1. Home
  2. SGMT vs TWIN Comparison

SGMT vs TWIN Comparison

Compare SGMT & TWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • TWIN
  • Stock Information
  • Founded
  • SGMT 2006
  • TWIN 1918
  • Country
  • SGMT United States
  • TWIN United States
  • Employees
  • SGMT N/A
  • TWIN N/A
  • Industry
  • SGMT
  • TWIN Industrial Machinery/Components
  • Sector
  • SGMT
  • TWIN Industrials
  • Exchange
  • SGMT Nasdaq
  • TWIN Nasdaq
  • Market Cap
  • SGMT 230.3M
  • TWIN 186.2M
  • IPO Year
  • SGMT 2023
  • TWIN N/A
  • Fundamental
  • Price
  • SGMT $6.15
  • TWIN $13.31
  • Analyst Decision
  • SGMT Strong Buy
  • TWIN Strong Buy
  • Analyst Count
  • SGMT 7
  • TWIN 1
  • Target Price
  • SGMT $26.57
  • TWIN $12.00
  • AVG Volume (30 Days)
  • SGMT 461.6K
  • TWIN 63.1K
  • Earning Date
  • SGMT 11-12-2025
  • TWIN 11-05-2025
  • Dividend Yield
  • SGMT N/A
  • TWIN 1.19%
  • EPS Growth
  • SGMT N/A
  • TWIN N/A
  • EPS
  • SGMT N/A
  • TWIN N/A
  • Revenue
  • SGMT N/A
  • TWIN $340,738,000.00
  • Revenue This Year
  • SGMT N/A
  • TWIN $10.79
  • Revenue Next Year
  • SGMT N/A
  • TWIN $8.43
  • P/E Ratio
  • SGMT N/A
  • TWIN N/A
  • Revenue Growth
  • SGMT N/A
  • TWIN 15.46
  • 52 Week Low
  • SGMT $1.73
  • TWIN $6.16
  • 52 Week High
  • SGMT $11.41
  • TWIN $13.80
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 30.58
  • TWIN 68.98
  • Support Level
  • SGMT $6.77
  • TWIN $12.79
  • Resistance Level
  • SGMT $7.35
  • TWIN $13.77
  • Average True Range (ATR)
  • SGMT 0.41
  • TWIN 0.60
  • MACD
  • SGMT -0.07
  • TWIN -0.05
  • Stochastic Oscillator
  • SGMT 5.57
  • TWIN 72.50

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

Share on Social Networks: